Abstract: FR-PO651

Comparison between Liraglutide and Sitagliptin Effects on Cardiac Function in Diabetic Patients with Renal Failure

Session Information

Category: Diabetes

  • 502 Diabetes Mellitus and Obesity: Clinical


  • Hiramatsu, Takeyuki, Konan Kosei Hospital, Konan Aichi, Japan

Diabetes mellitus with renal failure (DM-CRF) is a progressive multifactorial disease associated with cardiovascular complications. To prevent progression of cardiovascular complications in DM-CRF, glycemic control is important. But in DM-CRF, using of anti-diabetic agents(ADAs) were limited. In this study, we examined the efficacy of liraglutide or sitagliptin to treat type 2 diabetes patients with renal failure.


Seventy two type 2 diabetes patients with renal failure (eGFR< 60mL/min/1.73m2) were divided into two groups. Twenty four were used liraglutide 0.9 mg once a day (Group A), fourty eight were used sitagliptin 50mg once a day (Group B). ADAs were switched to these agents because of bad glycemic control. Moreover after that, all drugs were not changed during the study period. During 48 months of study period, we examined the blood pressure and renal function every three months. Echocardiography was examined at baseline and every 12 months after starting drugs to detect systolic and diastolic cardiac function.


Hemoglobin A1c, and systolic/diastolic blood pressure levels were gradually decreased in group A, but in group B was not. The eGFR value was not changed in both groups, however albuminuria was decreased significantly in both groups. Left ventricular ejection fraction(EF) was not changed during 48 months in both groups. But left atrial dimension(LAD) and tissue Doppler index(E/e’) in group A were improved significantly. In group B, at 48 months after using agents, E/e’ was worsened. No remarkable adverse events were seen in both groups.


These findings suggest that liraglutide and sitagliptin have similar effects on renal function, but according to cardiac diastolic function, liraglutide therapy is more beneficial for type 2 diabetes patients than sitagliptin therapy. Further studies with larger samples were needed to detect these effects.

In group A, diastolic funftion was improved, but in group B, was not.